Introduction
Treatment with a combination of lactam and an aminoglycoside is purported to be superior to lactam alone for sepsis on the basis of potential advantages such as in vitro synergism and prevention of development of resistance. [1] [2] [3] [4] [5] [6] [7] Textbooks and guidelines advise the combination for specific pathogens, such as Pseudomonas aeruginosa and other Gram negative bacteria, and for infections commonly caused by these pathogens. 8 9 In aiming for optimal antibiotic treatment of severe infections, hospital clinicians tend to use combination therapy despite the lack of direct evidence for its effectiveness. Observational studies show that 56% of patients with septic shock in the intensive care unit 10 are given lactam-aminoglycoside combination therapy.
We performed a systematic review and metaanalysis of randomised trials comparing lactamaminoglycoside combination therapy with lactam monotherapy for severe infections in patients without neutropenia.
Methods
We searched Medline, Embase, Lilacs, the Cochrane Library (all up to March 2003), conference proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) , and citations of included trials (see bmj.com for details).
We included all randomised and quasi-randomised trials that compared any lactam monotherapy with any 11 We excluded studies with a dropout rate above 30%, unless intention to treat analysis was given for mortality or failure outcomes, and studies with more than 15% of patients with neutropenia, neonates, and preterm babies.
The primary outcome assessed was all cause fatality by the end of study follow up and up to 30 days. Secondary outcomes included treatment failure, defined as death, non-resolving primary infection, any modification to allocated antibiotics, or any therapeutic invasive intervention not defined by protocol; bacteriological failure, defined as persistence of primary pathogen; bacterial and fungal superinfections and colonisation; adverse events; and length of hospital stay. We separated studies that compared the same lactam from studies that compared different lactams. We performed subgroup analyses for P aeruginosa infections, any Gram negative infection, bacteraemia, and specific sources of infection.
Two reviewers independently applied inclusion and exclusion criteria and extracted the data. We extracted outcomes by intention to treat, unless the reasons for exclusions were not presented. In this case, we used the presented results (per protocol analysis) in the main analysis and compared them with results using all randomised patients and assuming failure for dropouts. We expected heterogeneity with respect to outcomes and used the random effects model, comparing it to a fixed effect model. 12 The effect of study quality measures was examined through sensitivity analysis.
We examined a funnel plot of the log of the relative risk against the weight to estimate potential selection bias (such as publication bias) and to assess whether effect estimates were associated with study size.
Results
We evaluated 144 eligible randomised trials and included 64 in the review (see bmj.com). The trials included 7586 patients, nearly all adults, and were performed between the years 1968-2001. The median number of patients per trial was 87 (range 20-580). The major conditions were severe sepsis, pneumonia, or Gram negative infections (41 trials), abdominal infections (11 trials), urinary tract infections (7 trials), and Gram positive infections (5 trials). Allocation to antibiotics was empirical in 56 trials. The same lactam was compared in 20 trials, while all other trials compared one lactam to a different, narrower spectrum lactam combined with an aminoglycoside.
All cause fatality-Forty three trials including 5527 patients reported all cause fatality. There was no significant difference between monotherapy and combination therapy when we combined these studies (fig 1) . There was no difference among the 12 studies with 1381 patients that compared the same lactam or among studies that compared different lactams. The heterogeneity for this comparison was low.
Treatment failure-We compared clinical and bacteriological failures in 63 and 43 trials, respectively. For both comparisons, monotherapy was not significantly different from combination therapy among studies that compared the same lactam. Monotherapy was significantly superior to combination therapy among studies that compared different lactams. The overall comparison favoured monotherapy for clinical failure (0.87, 0.78 to 0.97; 6616 patients; number needed to treat 34, 20 to 147) and for bacteriological failure (0.86, 0.72 to 1.02; 3511 patients).
Subgroup analysis-Major effectiveness outcomes were compared within the defined patient subgroups: P aeruginosa infections, any Gram negative infection, bacteraemia, non-urinary tract infections, Gram positive infections, and endocarditis. We did not detect an advantage to combination therapy with any subgroup tested (see bmj.com).
Development of resistance-Combination therapy did not lower bacterial superinfection or colonisation rates, which we would have expected if combination therapy prevented the development of resistance. Relative risks tended to favour monotherapy for bacterial superinfections (0.79, 0.59 to 1.06). Rates of fungal superinfection were similar. Twenty six studies reported coverage rates of the allocated treatment, although outcomes were not related to coverage. Among studies with different lactams, the monotherapy lactam provided broader coverage than the combination lactam in 13 studies, the opposite occurring in two studies. Combined coverage of the lactam and the aminoglycoside equalled monotherapy in these studies.
Dropouts and adverse events-The dropout rate was 12.6% and similar in both study groups (1.01, 0.85 to 1.20, 24 studies, 3631 patients). Few patients (2%) discontinued treatment because of adverse events with no difference between study groups (0.89, 0.52 to 1.52, 15 studies, 3042 patients). Nephrotoxicity was more common with combination therapy in nearly all studies, and the combined relative risk was 0.36 (0.28 to 0.47, fig 2) , corresponding to a number needed to harm of 15 (14 to 17) for combination therapy.
Sensitivity analysis-Sensitivity analyses were carried out for measures of study quality. All sensitivity comparisons were non-significant. The advantage of monotherapy was more significant in trials that used some type of blinding. The funnel plot for treatment failure generated a nearly symmetrical "funnel distribution" (see bmj.com).
Discussion

Main findings
In this systematic review of all randomised trials we have shown that lactam-aminoglycoside combination therapy and lactam monotherapy for the treatment of sepsis have similar effects in patients without neutropenia.
Twenty trials compared the same lactam. All cause fatality, the most significant and objective outcome, was not reduced by the addition of aminoglycosides. Clinical and bacteriological failure, which may be prone to bias with non-blinded trials and are of much lesser relevance to patients, were not significantly different. However, rates of adverse events increased with the aminoglycoside. Nephrotoxicity was much more common with combination therapy.
Forty four trials compared a broad spectrum, usually novel, lactam with a "routine" combination regimen. Rates of appropriate antibiotic treatment with combination therapy and monotherapy were similar when reported. Fatality was not significantly different. Failures were significantly more common with combination therapy. Among all trials, we found no evidence for any potential prevention of infection by resistant isolates with combination therapy.
How should these findings be interpreted?
It can be debated which design appropriately examines the clinical interpretation of synergism, studies comparing same or different lactams. Synergism has been defined as a 2 log 10 or greater reduction in bacterial count with the combination versus that with each of the agents alone. 13 In studies comparing the same lactam this is directly tested, but the effect of increasing the antibiotic spectrum cannot be separated from a synergistic effect. In studies comparing different lactams the spectrum of coverage was similar in both arms. However, synergism can be examined only indirectly. If we assume that the aminoglycoside offers more than its additional coverage, the combination arm should perform as well, or better, than the broader With the former design we did not detect an advantage to the combination, while with the latter we found an advantage to monotherapy.
Weaknesses of the study
The quality of included studies was poor overall. We did not detect bias induced by any of the measures assessed. We could not obtain data on all cause fatality for 33% of studies. It is unlikely that missing results would shift the results for studies comparing the same lactam, but it is of concern that studies comparing different lactams may not detect important harm to patients.
Our assessment of treatment effects for patients with P aeruginosa, Gram negative, and blood infections relies on subgroup analysis. We did not detect an advantage for combination therapy among these patients. Only few patients with documented P aeruginosa infections could be evaluated. The types of infections addressed by included studies suggest that further infections were caused by this pathogen.
Does further evidence support our findings?
Suggestions for an advantage for combination treatment for P aeruginosa rely mostly on a prospective observational study.
14 A similar study focusing on Klebsiella bacteraemia found an advantage for combination therapy only among patients with hypotension, 15 while other studies have not found such an advantage. [16] [17] [18] [19] In a comparison of lactam monotherapy with lactam-aminoglycoside combination therapy restricted to patients with neutropenia we found no advantage to combination treatment. 20 Although the approach to the management of patients with and without neutropenia is separated in clinical practice, this similarity supports a biological basis underlying our results. 
